SAREUM HOLDINGS PLC

Report Publication Announcement • Mar 12, 2024

National Storage Mechanism | Additional information

RNS Number : 5564G

Sareum Holdings PLC

12 March 2024

Sareum Holdings PLC

("Sareum" or the "Company")

Notice of Interim Results and Trading Update

Cambridge, UK, March 12 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, provides notice of the timing of publication of its interim results, a trading update and an update on its Equity Prepayment Facility with RiverFort Global Opportunities PCC Ltd ("RiverFort").

The Company announces that its results for the half-year to 31 December 2023 will be published in the week beginning 25 March 2024, in which the Company expects to report an o perating loss of £2.5 million (2022: £1.7 million), reflecting the cost of continued and additional investment into clinical research conducted during the period for the furtherance of its SDC-1801 autoimmune disease programme.

As announced on 3 August 2023, the Company entered into an Equity Prepayment Facility with RiverFort (the "Facility"). The Company has drawn £2.3 million to date pursuant to the Facility from two prepayment deposits. The Company currently has an outstanding balance of circa £1.3 million under the Facility. Any balances pursuant to the Facility are not due for repayment until August 2025 (the "Maturity Date") and the Company expects to settle all balances by the issuance of Placing Shares prior to the Maturity Date.

The Company previously announced that the Facility included a committed third tranche prepayment deposit of £300,000, which remained subject to the terms and conditions of the Facility. Due to downward pressure on the Company's share price, Sareum has been unable to draw down the third prepayment under the Facility. The Company is in discussions to assess alternative funding arrangements and has taken steps to preserve its immediate capital utilisation. Providing alternative funding is secured, the Board of Directors remains confident that the Company is on course to deliver topline Phase 1a results in Q2 2024.

Application for admission to trading

In accordance with the terms of the Facility, Sareum has issued a further 1.5 million Placing Shares. Application will be made to the London Stock Exchange for the admission of the 1.5 million Placing Shares to trading on AIM ("Admission").  It is expected that Admission will occur at 8.00am (London Time) on Monday 18 March 2024.

Immediately following Admission, the Company will have 71,761,878 ordinary shares of 1.25 pence each in issue; therefore, the total voting rights in the Company will be 71,761,878. This figure may be used by shareholders in the Company as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Terms and definitions used in this announcement shall have the same meaning as ascribed to them in the Company's announcement dated 3 August 2023, unless otherwise stated.

- Ends -

For further information, please contact: 

Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations	01223 497700 ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Peel Hunt LLP (Joint Corporate Broker) James Steel / P atrick Birkholm	020 7418 8900
Hybridan LLP (Joint Corporate Broker) Claire Noyce	020 3764 2341
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / K umail Waljee	0203 709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSFWFDEELSESD